Physician profile
Jesse Balls
NPI 1487026191
$675.46
in general payments reported to CMS, 2019-2025
15 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $134 · 2023: $149 · 2024: $111 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $153.02 | 2021-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $144.71 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $119.01 | 2023 | Bexsero |
| Exact Sciences Corporation | $47.44 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $29.78 | 2023 | Wavewriter Alpha Prime 16 |
| Welch Allyn | $28.57 | 2021 | |
| Abbvie INC. | $26.92 | 2022 | |
| Dexcom, INC. | $21.69 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.86 | 2025 | Caplyta |
| Pfizer INC. | $16.31 | 2024 | |
| Abbott Laboratories | $15.93 | 2022 | |
| Janssen Biotech, INC. | $14.82 | 2025 | Tremfya |
| Astellas Pharma US INC | $13.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.51 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Balls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.